Impending biologics patent expiries creates huge opportunity for European biosimilars makers

The biosimilars manufacturing industry is at a nascent stage. However, the impending patent expiries of biologics are anticipated to result in the introduction of several new biosimilars and provide impetus to market development.

New analysis from Frost & Sullivan, titled Analysis of European Biosimilars Market, finds that the market earned revenue of around $172.0 million in 2010 and estimates this to reach approximately $3.9 billion in 2017, increasing at a compound annual growth rate (CAGR) of 56.7% from 2010 to 2017. This study covers the existing biosimilars segments (erythropoietin, granulocyte colony stimulating factors and human growth hormones) and emerging biosimilars segments (monoclonal antibodies, insulin and interferon - alpha and beta).

“The expiration of patents and other intellectual property rights of biological innovators over the next decade opens up opportunities for biosimilars to enter the market and increase industry competition,” notes Frost & Sullivan Research analyst Srinivas Sashidhar, adding: “Price reduction strategies will ensure increased adoption among physicians and patients alike, spurring market advancement.”